A FIRST-IN-HUMAN PHASE 1 CLINICAL STUDY OF ACHN-975, A FIRST-IN-CLASS AGENT BEING DEVELOPED FOR THE TREATMENT OF SERIOUS MULTIDRUG-RESISTANT GRAM-NEG
$2,499,000FY2012Department of the ArmyDOD
Achaogen, Inc., South San Francisco CA
Achaogen, Inc., South San Francisco CA